Paradigm Medical Industr... (CE) (USOTC:PDMI)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Paradigm Medical Industr... (CE) Charts. Click Here for more Paradigm Medical Industr... (CE) Charts.](/p.php?pid=staticchart&s=NO%5EPDMI&p=8&t=15)
Paradigm Medical Industries, Inc. (OTCBB: PDMI.OB) has launched several
internal programs aimed at expanding its position in the U.S. and global
diagnostic ultrasound and early glaucoma detection markets. The
Company’s initial efforts are aimed directly at the $25-million
opportunity for its P60 Ultrasound BioMicroscope (UBM) and the growing
glaucoma detection markets.
“We are redirecting our efforts to reposition our leading products in
the ultrasound market, where the Company has been the premier developer
of new, high-technology devices,” said Paradigm Medical’s new President,
Stephen Davis. “Our short-term goal is focused on new design
enhancements for our three proprietary products: the P60 UBM, the Blood
Flow Analyzer™ (BFA), and the LD400 autoperimeter, and increasing sales
of the Glaid-PERG throughout North America.”
The Glaid-PERG electrophysiology instrument is used for the early
detection of glaucoma. Paradigm Medical has an exclusive agreement with
LACE Elettronica srl (Rome, Italy) to distribute the latter’s Glaid-PERG
device. “We are also reinforcing other global collaborations in the
U.S., Europe and Asia,” Mr. Davis noted.
“The U.S. market for ophthalmic diagnostic ultrasound devices is over
$250 million and growing at more than 5% per year. The global
opportunity is probably double that,” Mr. Davis added. “Paradigm Medical
is also readying several new products that could be commercialized by
mid-2009. We are known in the industry as ‘The UBM Company,’ based on
our innovation and array of ultrasound devices for the ophthalmic and
medical industries. And we remain dedicated to not only growing our
share of the market but also to expanding the size of the market through
new proprietary products and technology.”
The Company’s P60 UBM is used for viewing structures in the eye involved
with glaucoma pathologies and surgical procedures. The Blood Flow
Analyzer™ is used for early detection and treatment management of
glaucoma and other retina related diseases. The LD400 Autoperimeter is
used to measure patient visual fields to determine the severity of
glaucoma and to aid in managing the disease.
Paradigm Medical Industries, Inc. is a leader in ultrasound devices, and
glaucoma detection and management products.
This press release contains statements that, if not verifiable historic
fact, may be viewed as forward-looking statements that could predict
future events and outcomes with respect to Paradigm and its business.
The predictions embodied in these statements will involve risk and
uncertainties and, accordingly, actual results may differ significantly
from the results discussed or implied in such forward-looking statements.